Is erlotinib effective for advanced lung cancer?

Erlotinib is a small molecule tyrosine kinase inhibitor and belongs to the first generation of targeted drugs. It inhibits tumor growth and metastasis by inhibiting the EGFR signaling pathway. This mechanism of action makes erlotinib outstanding in the treatment of advanced non-small cell lung cancer targeting EGFR gene mutations.

For patients with advanced non-small cell lung cancer with EGFR gene mutations, erlotinib is more effective than traditional chemotherapy as a first- or second-line treatment. The first-line progression-free survival can reach about 11 months, and is well tolerated by patients with relatively few side effects.

Erlotinib can effectively control the progression of the disease, delay tumor growth and metastasis, thereby improving the patient's quality of life. By inhibiting tumor growth and metastasis, erlotinib helps prolong patients' survival and gives them more treatment time and opportunities.

Erlotinib is mainly used to treat EGFR driver gene mutation-positive locally advanced or metastatic non-small cell lung cancer. For patients whose disease continues to progress despite first- and second-line chemotherapy, erlotinib can be used as a third-line drug.

Although erlotinib is effective in the treatment of advanced lung cancer, patients still need to pay attention to its side effects during use. Common side effects include skin side effects such as rash and itching, gastrointestinal side effects such as diarrhea and nausea, and liver side effects such as elevated transaminases. In addition, resistance to erlotinib may develop after a period of use, which requires adjustment of the treatment plan according to the patient's specific situation.

During the period of using erlotinib, patients need to regularly monitor relevant indicators and carry out standardized treatment under the guidance of a doctor. At the same time, maintaining good living habits and mentality are also important factors in improving treatment effects.